uniQure N.V. Cost of Revenue
uniQure N.V. (QURE) reported Cost of Revenue of $219.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-05-05
- uniQure N.V. cost of goods and services sold for the quarter ending 2026-03-31 was $219.00K, a 11.17% increase year-over-year.
- uniQure N.V. cost of goods and services sold for the quarter ending 2025-12-31 was $435.00K, a 29.73% decline year-over-year.
- uniQure N.V. cost of goods and services sold for the quarter ending 2025-09-30 was $398.00K, a 50.76% increase year-over-year.
- uniQure N.V. cost of goods and services sold for the quarter ending 2025-06-30 was $656.00K, a 180.34% increase year-over-year.
- uniQure N.V. cost of goods and services sold for fiscal 2025 was $1.69M, a 33.07% increase from fiscal 2024.
- uniQure N.V. cost of goods and services sold for fiscal 2024 was $1.27M, a 1849.23% increase from fiscal 2023.
- uniQure N.V. cost of goods and services sold for fiscal 2023 was $65.00K, a 94.82% decline from fiscal 2022.
- uniQure N.V. cost of goods and services sold for fiscal 2022 was $1.25M, a 94.98% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-03-31 | $219.00K 10-Q · filed 2026-05-05 | $654.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.05M derived: sum of 3 quarters · filed 2026-05-05 | $1.71M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $833.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.49M derived: sum of 3 quarters · filed 2026-03-02 | $1.69M 10-K · filed 2026-03-02 |
| 2025-09-30 | $398.00K 10-Q · filed 2025-11-10 | $1.05M derived: sum of 2 quarters · filed 2025-11-10 | $1.25M 10-Q · filed 2025-11-10 | $1.87M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $656.00K 10-Q · filed 2025-07-29 | $853.00K 10-Q · filed 2025-07-29 | $1.47M derived: sum of 3 quarters · filed 2026-05-05 | $1.74M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $197.00K 10-Q · filed 2026-05-05 | $816.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.08M derived: sum of 3 quarters · filed 2026-05-05 | $1.31M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $619.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $883.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.12M derived: sum of 3 quarters · filed 2026-03-02 | $1.27M 10-K · filed 2026-03-02 |
| 2024-09-30 | $264.00K 10-Q · filed 2025-11-10 | $498.00K derived: sum of 2 quarters · filed 2025-11-10 | $648.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $234.00K 10-Q · filed 2025-07-29 | $384.00K 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $150.00K 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $65.00K 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $1.25M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.80M derived: sum of 2 quarters · filed 2024-02-28 | $24.98M derived: sum of 3 quarters · filed 2024-02-28 | $24.98M 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $23.18M derived: sum of 2 quarters · filed 2022-11-02 | $23.18M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $23.18M 10-Q · filed 2022-08-08 | $23.18M 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | $2.90M 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $1.65M 10-K · filed 2021-03-01 | |||
| 2018-12-31 | $1.20M 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $817.00K 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $1.35M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |